Silexion Therapeutics (NASDAQ:SLXN) Cut to Sell at Wall Street Zen

Silexion Therapeutics (NASDAQ:SLXN) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other analysts also recently issued reports on the stock. Zacks Research raised shares of Silexion Therapeutics to a “hold” rating in a report on Tuesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Wednesday, October 8th. Finally, Litchfield Hills Research started coverage on shares of Silexion Therapeutics in a report on Monday, December 15th. They set a “buy” rating for the company. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $75.00.

Silexion Therapeutics Stock Down 1.2%

Shares of SLXN stock opened at $2.40 on Friday. The stock’s 50 day simple moving average is $2.98 and its 200 day simple moving average is $6.88. Silexion Therapeutics has a twelve month low of $2.13 and a twelve month high of $51.75. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.97 and a current ratio of 3.97. The company has a market capitalization of $7.51 million, a price-to-earnings ratio of -0.22 and a beta of -0.06.

Silexion Therapeutics (NASDAQ:SLXN) last announced its earnings results on Wednesday, November 12th. The company reported ($2.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.40) by $0.52.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.